关注
Shruti Bhatt
标题
引用次数
引用次数
年份
PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells
JD Kahn, PG Miller, AJ Silver, RS Sellar, S Bhatt, C Gibson, M McConkey, ...
Blood, The Journal of the American Society of Hematology 132 (11), 1095-1105, 2018
1972018
Inhibition of USP10 induces degradation of oncogenic FLT3
EL Weisberg, NJ Schauer, J Yang, I Lamberto, L Doherty, S Bhatt, ...
Nature chemical biology 13 (12), 1207-1215, 2017
1152017
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
KA Sarosiek, LE Cavallin, S Bhatt, NL Toomey, Y Natkunam, W Blasini, ...
Proceedings of the National Academy of Sciences 107 (29), 13069-13074, 2010
1052010
Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia
S Bhatt, MS Pioso, EA Olesinski, B Yilma, JA Ryan, T Mashaka, B Leutz, ...
Cancer cell 38 (6), 872-890. e6, 2020
992020
miR-155 regulates HGAL expression and increases lymphoma cell motility
LN Dagan, X Jiang, S Bhatt, E Cubedo, K Rajewsky, IS Lossos
Blood, The Journal of the American Society of Hematology 119 (2), 513-520, 2012
932012
Statins enhance efficacy of venetoclax in blood cancers
JS Lee, A Roberts, D Juarez, TTT Vo, S Bhatt, L Herzog, S Mallya, ...
Science translational medicine 10 (445), eaaq1240, 2018
882018
CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma
S Bhatt, BM Ashlock, Y Natkunam, V Sujoy, JR Chapman, JC Ramos, ...
Blood, The Journal of the American Society of Hematology 122 (7), 1233-1242, 2013
882013
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma
S Bhatt, BM Ashlock, NL Toomey, LA Diaz, EA Mesri, IS Lossos, ...
The Journal of clinical investigation 123 (6), 2616-2628, 2013
762013
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
AS Sperling, M Burgess, H Keshishian, JA Gasser, S Bhatt, M Jan, ...
Blood, The Journal of the American Society of Hematology 134 (2), 160-170, 2019
622019
miR-181a negatively regulates NF-κB signaling and affects activated B-cell–like diffuse large B-cell lymphoma pathogenesis
GA Kozloski, X Jiang, S Bhatt, J Ruiz, F Vega, R Shaknovich, A Melnick, ...
Blood, The Journal of the American Society of Hematology 127 (23), 2856-2866, 2016
582016
Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma
E Cubedo, AJ Gentles, C Huang, Y Natkunam, S Bhatt, X Lu, X Jiang, ...
Blood, The Journal of the American Society of Hematology 119 (23), 5478-5491, 2012
502012
Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma
S Bhatt, J Matthews, S Parvin, KA Sarosiek, D Zhao, X Jiang, E Isik, ...
Blood, The Journal of the American Society of Hematology 126 (13), 1555-1564, 2015
382015
Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell–dependent cytotoxicity
S Bhatt, S Parvin, Y Zhang, HM Cho, K Kunkalla, F Vega, JM Timmerman, ...
Blood, The Journal of the American Society of Hematology 129 (16), 2246-2256, 2017
312017
Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma
JM Matthews, S Bhatt, MP Patricelli, TK Nomanbhoy, X Jiang, ...
Blood, The Journal of the American Society of Hematology 128 (2), 239-248, 2016
252016
Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors
D Zhu, S Bhatt, X Lu, F Guo, H Veelken, DK Hsu, FT Liu, S Alvarez Cubela, ...
Leukemia 29 (7), 1587-1599, 2015
232015
Interleukin 21–its potential role in the therapy of B-cell lymphomas
S Bhatt, KA Sarosiek, IS Lossos
Leukemia & lymphoma 58 (1), 17-29, 2017
222017
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re‐induction chemotherapy
JS Garcia, S Bhatt, G Fell, AS Sperling, M Burgess, H Keshishian, B Yilma, ...
American journal of hematology 95 (3), 245-250, 2020
162020
Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2
SK Dey, M Saini, C Dhembla, S Bhatt, AS Rajesh, V Anand, HK Das, ...
Journal of Biomolecular Structure and Dynamics 40 (24), 14067-14083, 2022
152022
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
S Adamia, S Bhatt, K Wen, Z Chyra, GG Fell, YT Tai, MS Pioso, I Abiatari, ...
Leukemia 36 (4), 1088-1101, 2022
122022
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy
PG Miller, AS Sperling, C Mayerhofer, ME McConkey, JM Ellegast, ...
Blood 142 (24), 2079-2091, 2023
102023
系统目前无法执行此操作,请稍后再试。
文章 1–20